Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer - Related Studies

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

This study is ongoing, but not recruiting participants.

Study NCT00436709. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms

3	More general conditions related to this trial
		Breast Diseases
		Neoplasms
		Neoplasms by Site
		Skin Diseases

4	Interventions listed in this trial
		bevacizumab
		cyclophosphamide
		doxorubicin hydrochloride
		pegfilgrastim
		adjuvant therapy
		flow cytometry
		immunoenzyme technique
		immunologic technique
		immunoscintigraphy
		laboratory biomarker analysis

5	Additional drug interventions recognized in this trial
		Doxorubicin
		Paclitaxel

6	More general drug interventions related to this trial
		Alkylating Agents
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antibiotics, Antineoplastic
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antineoplastic Agents, Phytogenic
		Antirheumatic Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		Memorial Sloan-Kettering Cancer Center
		National Cancer Institute (NCI)